<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05123820</url>
  </required_header>
  <id_info>
    <org_study_id>ID-087-105</org_study_id>
    <secondary_id>2021-003615-26</secondary_id>
    <nct_id>NCT05123820</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effect of Co-administered ACT-1014-6470 on the Pharmacokinetics of Omeprazole and Midazolam</brief_title>
  <official_title>A Single-center, Open-label, Two-period, Fixed-sequence Study to Investigate the Effect of a Single Oral Dose of ACT-1014-6470 on the Pharmacokinetics of Omeprazole, Midazolam, and Their Metabolites in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idorsia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idorsia Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study on whether ACT-1014-6470 has an effect on how the body takes up, distributes and gets&#xD;
      rid of omeprazole and midazolam in healthy male subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Two-period, fixed-sequence study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of ACT-1014-6470, midazolam and omeprazole.</measure>
    <time_frame>Total duration: up to 11 days</time_frame>
    <description>The plasma pharmacokinetic parameters of ACT-1014-6470, midazolam and omeprazole will be derived by non-compartmental analysis of the plasma concentration-time profiles.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach Cmax (tmax) of ACT-1014-6470, midazolam and omeprazole.</measure>
    <time_frame>Total duration: up to 11 days</time_frame>
    <description>The plasma pharmacokinetic parameters of ACT-1014-6470, midazolam and omeprazole will be derived by non-compartmental analysis of the plasma concentration-time profiles.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The area under the plasma concentration-time curve (AUC) from zero to time t of the last measured concentration above the limit of quantification (AUC0-t) of ACT-1014-6470, midazolam and omeprazole.</measure>
    <time_frame>Total duration: up to 11 days</time_frame>
    <description>The plasma pharmacokinetic parameters of ACT-1014-6470, midazolam and omeprazole will be derived by non-compartmental analysis of the plasma concentration-time profiles.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve [AUC(0-12)] of omeprazole.</measure>
    <time_frame>Total duration: up to 9 days</time_frame>
    <description>The plasma pharmacokinetic parameters of omeprazole will be derived by non-compartmental analysis of the plasma concentration-time profile.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve [AUC(0-24)] of midazolam and omeprazole.</measure>
    <time_frame>Total duration: up to 11 days</time_frame>
    <description>The plasma pharmacokinetic parameters of midazolam and omeprazole will be derived by non-compartmental analysis of the plasma concentration-time profiles.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve [AUC(0-inf)] of ACT-1014-6470, midazolam and omeprazole.</measure>
    <time_frame>Total duration: up to 11 days</time_frame>
    <description>The plasma pharmacokinetic parameters of ACT-1014-6470, midazolam and omeprazole will be derived by non-compartmental analysis of the plasma concentration-time profiles.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent total body clearance (CL/F) of ACT-1014-6470, midazolam and omeprazole.</measure>
    <time_frame>Total duration: up to 11 days</time_frame>
    <description>The plasma pharmacokinetic parameters of ACT-1014-6470, midazolam and omeprazole will be derived by non-compartmental analysis of the plasma concentration-time profiles.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The terminal half-life (t½) of ACT-1014-6470, midazolam and omeprazole.</measure>
    <time_frame>Total duration: up to 11 days</time_frame>
    <description>The plasma pharmacokinetic parameters of ACT-1014-6470, midazolam and omeprazole will be derived by non-compartmental analysis of the plasma concentration-time profiles.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) of 1-hydroxymidazolam and 5-hydroxyomeprazole.</measure>
    <time_frame>Total duration: up to 11 days</time_frame>
    <description>The plasma pharmacokinetic parameters of 1-hydroxymidazolam and 5-hydroxyomeprazole will be derived by non-compartmental analysis of the plasma concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach Cmax (tmax) of 1-hydroxymidazolam and 5-hydroxyomeprazole.</measure>
    <time_frame>Total duration: up to 11 days</time_frame>
    <description>The plasma pharmacokinetic parameters of 1-hydroxymidazolam and 5-hydroxyomeprazole will be derived by non-compartmental analysis of the plasma concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The area under the plasma concentration-time curve (AUC) from zero to time t of the last measured concentration above the limit of quantification (AUC0-t) of 1-hydroxymidazolam and 5-hydroxyomeprazole.</measure>
    <time_frame>Total duration: up to 11 days</time_frame>
    <description>The plasma pharmacokinetic parameters of 1-hydroxymidazolam and 5-hydroxyomeprazole will be derived by non-compartmental analysis of the plasma concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve [AUC(0-12)] of 5-hydroxyomeprazole.</measure>
    <time_frame>Total duration: up to 11 days</time_frame>
    <description>The plasma pharmacokinetic parameters of 5-hydroxyomeprazole will be derived by non-compartmental analysis of the plasma concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve [AUC(0-24)] of 1-hydroxymidazolam and 5-hydroxyomeprazole.</measure>
    <time_frame>Total duration: up to 11 days</time_frame>
    <description>The plasma pharmacokinetic parameters of 1-hydroxymidazolam and 5-hydroxyomeprazole will be derived by non-compartmental analysis of the plasma concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve [AUC(0-inf)] of 1-hydroxymidazolam and 5-hydroxyomeprazole.</measure>
    <time_frame>Total duration: up to 11 days</time_frame>
    <description>The plasma pharmacokinetic parameters of 1-hydroxymidazolam and 5-hydroxyomeprazole will be derived by non-compartmental analysis of the plasma concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The terminal half-life (t½) of 1-hydroxymidazolam and 5-hydroxyomeprazole.</measure>
    <time_frame>Total duration: up to 11 days</time_frame>
    <description>The plasma pharmacokinetic parameters of 1-hydroxymidazolam and 5-hydroxyomeprazole will be derived by non-compartmental analysis of the plasma concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The metabolic ratio (MR) of 1-hydroxymidazolam to midazolam .</measure>
    <time_frame>Total duration: up to 11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The metabolic ratio (MR) of 5-hydroxyomeprazole to omeprazole.</measure>
    <time_frame>Total duration: up to 11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-emergent adverse events as a measure of safety and tolerability.</measure>
    <time_frame>Total duration: up to 11 days</time_frame>
    <description>An adverse event is an unfavorable and unintended sign (including an abnormal laboratory finding, an abnormal electrocardiogram). A treatment-emergent adverse event is any adverse event temporally associated with the use of a study treatment, whether or not considered related to the study treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Drug Drug Interaction</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ACT-1014-6470, Midazolam and Omeprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Period A (Day 1 to Day 2) The plan is that all participants will receive treatment A and then treatment B.&#xD;
A single oral dose of midazolam 2 mg and a single oral dose of omeprazole 20 mg on Day 1.&#xD;
Treatment Period B (Day 8 to Day 11)&#xD;
A single oral dose of 100 mg ACT-1014-6470, a single oral dose of 20 mg omeprazole, and a single oral dose of 2 mg midazolam on Day 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment period A</intervention_name>
    <description>Midazolam solution for oral administration. Omeprazole hard capsule for oral administration.</description>
    <arm_group_label>ACT-1014-6470, Midazolam and Omeprazole</arm_group_label>
    <other_name>Midazolam and Omeprazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment period B</intervention_name>
    <description>ACT-1014-6470 soft capsule for oral administration. Midazolam solution for oral administration. Omeprazole hard capsule for oral administration.</description>
    <arm_group_label>ACT-1014-6470, Midazolam and Omeprazole</arm_group_label>
    <other_name>ACT-1014-6470, Midazolam and Omeprazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent in a language understandable to the participant prior to any&#xD;
             study-mandated procedure.&#xD;
&#xD;
          -  Healthy male participant aged between 18 and 45 years (inclusive) at Screening.&#xD;
&#xD;
          -  Body mass index of 18.5 to 28.0 kg/m2 (inclusive) at Screening.&#xD;
&#xD;
          -  Systolic blood pressure 100-140 mmHg, diastolic blood pressure 50-90 mmHg, and pulse&#xD;
             rate 45-90 beats per minute (inclusive), measured on either arm, after 5 min in the&#xD;
             supine position at Screening and on Day -1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous exposure to ACT-1014-6470.&#xD;
&#xD;
          -  Known hypersensitivity to ACT-1014-6470, omeprazole, substituted benzimidazoles,&#xD;
             midazolam, or treatments of the same pharmacological classes, or any of their&#xD;
             excipients.&#xD;
&#xD;
          -  History or clinical evidence of any disease and/or existence of any surgical or&#xD;
             medical condition, which in the opinion of the investigator, are likely to interfere&#xD;
             with the absorption, distribution, metabolism, or excretion of the study treatment&#xD;
             (appendectomy and herniotomy allowed if performed more than 12 weeks prior to&#xD;
             administration of [first] study treatment, cholecystectomy not allowed).&#xD;
&#xD;
          -  Previous treatment with any prescribed medications (including vaccines [Vaccination&#xD;
             regimen against COVID-19 completed less than 2 weeks prior to first study treatment&#xD;
             administration or any vaccination against COVID-19 planned before end-of-study]) or&#xD;
             OTC medications (including herbal medicines such as St John's Wort, homeopathic&#xD;
             preparations, vitamins, and minerals) within 3 weeks prior to first study treatment&#xD;
             administration.&#xD;
&#xD;
          -  Legal incapacity or limited legal capacity at Screening.&#xD;
&#xD;
          -  Participant with rare inherited issues of fructose intolerance, glucose-galactose&#xD;
             malabsorption, or sucrase-isomaltase insufficiency.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Idorsia Pharmaceuticals Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Disclosure Desk</last_name>
    <phone>+41 58 844 1977</phone>
    <email>clinical-trials-disclosure@idorsia.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CEPHA s.r.o.</name>
      <address>
        <city>Pilsen</city>
        <zip>32300</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 5, 2021</study_first_submitted>
  <study_first_submitted_qc>November 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ACT-1014-6470</keyword>
  <keyword>Omeprazole</keyword>
  <keyword>Midazolam</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

